A husband visits a local pharmacy to fill his ailing wife’s monthly asthma prescription, which costs $110. What he doesn’t know — and what his pharmacist can’t tell him — is that her Part D insurance plan isn’t helping to reduce the cost. In fact, it’s only hurting. They could have saved $35 by paying out-of-pocket.
That’s the kind of problem President Donald Trump aims to solve with his new drug price plan. The blueprint he released earlier this month is practical, focused squarely on executive actions that will force drug companies toward greater transparency. But will the White House’s pragmatism be enough?